RAM
PRME icon

Riggs Asset Management’s Prime Medicine PRME Stock Holding History

Riggs Asset Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-36
Closed -$252 – 737
2024
Q1 		$252 Buy
+36
New +$273 ﹤0.01% 629

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Riggs Asset Management's PRME Position: Q2 2024 in Review

Riggs Asset Management sold out of Prime Medicine (PRME) in Q2 2024, closing a stake of 36 shares — an estimated $252 sold.

Riggs Asset Management first reported a position in PRME in Q1 2024 and held it in 1 quarter. The position peaked at $252 in Q1 2024. 122 funds tracked by Wall St. Rank hold PRME as of Q2 2024.

  • Riggs Asset Management reported no remaining Prime Medicine position as of Q2 2024 after selling out during the quarter.
  • Riggs Asset Management sold 36 Prime Medicine shares in Q2 2024, an estimated $252.
  • Riggs Asset Management first reported a position in Prime Medicine in Q1 2024 and held it in 1 quarter.
  • Riggs Asset Management's Prime Medicine position peaked at $252 in Q1 2024.
  • 122 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2024.

Based on Riggs Asset Management's 13F filing for Q2 2024, filed 29 Jul 2024.